A Prospective Multicenter Study to Observe the Effectiveness on Ulcerative Colitis and Predictive Factors of Clinical Response in Korean Patients Treated With Adalimumab (EUREKA Study)
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Adalimumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms EUREKA
- Sponsors AbbVie
- 19 May 2020 Results published in Gasteroenterology in conjunction with Digestive Disease Week 2020.
- 28 Nov 2018 Status changed from active, no longer recruiting to completed.
- 13 Aug 2018 Planned End Date changed from 30 Jul 2018 to 31 Oct 2018.